Testosterone deficiency in men is a common but often-missed diagnosis. After confirmation of the diagnosis, exclusion of any reversible causes, or contraindications to the use of testosterone, replacement therapy may be offered. Methods of replacement include injectable testosterone esters, transdermal testosterone (gels or patches), or oral testosterone in the form of testosterone undecanoate. Men receiving testosterone therapy should be followed according to a standardized monitoring plan; testosterone levels should be assessed 2 to 3 months after therapy is initiated, followed by annual examinations to assess whether symptoms have improved and whether the patient is experiencing adverse events.
Testosterone can be administered orally, transdermally, or by injection to improve a hypogonadal man’s sense of well-being, sexual function, bone density, and muscle strength.
Hypogonadism affects approximately 40% of men aged 45 or older, although less than 5% of these men are actually diagnosed and treated for the condition. Despite some controversy, testosterone therapy has been established as a safe and effective principal treatment for hypogonadism for nearly 70 years.
In the last decade, studies have improved our understanding of hypogonadism and have helped clarify its prevalence and associated comorbid illnesses.[1-3]
The principal causes of hypogonadism are testicular failure (primary hypogonadism), pituitary and/or hypothalamic failure (secondary hypogonadism), and age-related dysfunction (generally a combination of primary and secondary hypogonadism).
The most common causes of primary hypogonadism include Klinefelter syndrome, myotonic dystrophy, vanishing testicle syndrome (congenital anorchidism), and radiation-induced or chemotherapy-induced hypogonadism.
Common congenital causes of secondary hypogonadism include Kallmanns syndrome and idiopathic hypogonadotropic hypogonadism (IHH). Causes of acquired secondary hypogonadism include adult-onset IHH, hematochromatosis, and pituitary tumors, including prolactinomas.
Confirming a diagnosis of hypogonadism generally involves three components. First, there should be symptoms of androgen deficiency; second, there should be unequivocal biochemical evidence of low testosterone levels; and third, there should be a positive response to testosterone replacement therapy. If all three of these diagnostic components are not present, the practitioner should question the diagnosis and consider discontinuing testosterone therapy.
Symptoms of hypogonadism can include mood changes such as irritability or increased sadness, reduced libido, low energy, fatigue, decreased muscle bulk, decreased muscle strength, muscle aches, hot flushes, decreased ability to concentrate on tasks, lack of morning erections or less rigid erections, decreased volume of ejaculate, and infertility.
Physical signs of hypogonadism can include a change in body composition with more central body fat, gynecomastia, testicular atrophy (more common with primary hypogonadism), muscular atrophy, osteoporotic fractures, and height loss.
As a comorbid condition, hypogonadism occurs with increased frequency among men with osteoporosis, osteoporotic fractures, type 2 diabetes, metabolic syndrome, and chronic obstructive pulmonary disease (COPD).
Table 1 lists some of the specific and less-specific symptoms and signs related to androgen deficiency hypogonadism. It remains challenging for the physician to detect hypogonadism as many of the symptoms of androgen deficiency are not specific on their own and gain more significance by the company they keep. The less-specific symptoms should prompt investigation for hypogonadism when they occur in concert with specific symptoms.
Available testosterone tests measure the total amount of the hormone in the serum, the free amount in the serum, or the bioavailable amount, which is a combination of free and loosely albumin-bound testosterone.
While it is a point of some controversy, the author recommends the bioavailable testosterone test as the best for confirming low serum testosterone levels because clinicians have found it enables better distinction of patients who are hypogonadal.
Bioavailable testosterone testing is available from a number of laboratories in British Columbia. Although some guidelines suggest first obtaining a total testosterone level, sex hormone binding globulin (SHBG) levels can vary widely and lead to erroneous results unless a bioavailable testosterone level is also obtained.[4,5]
Physicians should be aware that testosterone levels fluctuate even in healthy males. For this reason a eugonadal male will occasionally have a transiently low testosterone level. Repeat testing will generally reveal normal values. Conversely, a hypogonadal male will occasionally have testosterone values in the low-normal range, and repeat testing will then find a low testosterone level and confirm the original clinical impression.[5-7]
Patients who test low for testosterone should also be tested for luteinizing hormone (LH), follicle stimulating hormone (FSH), and prolactin levels. Prolactin elevation should prompt consideration of a pituitary tumor. Ferritin levels should be checked in cases of hypogonadotropic hypogonadism to exclude hemochromatosis.[4,5]
Testosterone levels can be affected by general health status. Acute illness will cause a transient drop in testosterone. To avoid confusion and overdiagnosis of hypogonadism, practitioners should remember that testosterone measurements of men who are sick enough to require hospitalization cannot be relied on for definitive diagnoses.
Ideally, the patient should be unstressed and physiologically stable before testing. It is also important to take blood samples for testosterone before 10 a.m. to avoid registering the normal circadian dip in testosterone that occurs in the afternoon.[4-6]
Screening for hypogonadism in the general population is not indicated. Case finding in selected circumstances is, however, acceptable, such as when testing for low testosterone is part of the workup for osteoporosis or unexplained anemia.
Other useful tests may include assessment for sleep apnea in men with secondary hypogonadism, measurement of fasting blood glucose and lipids, and a DEXA measurement of bone mineral density (BMD) to exclude concomitant osteoporosis.[4,5]
In men with secondary hypogonadism there is a possibility of pituitary disease. Although imaging of the pituitary gland is not required for most such men, CT or MRI scanning of the pituitary gland should be considered for men who develop secondary hypogonadism before age 50, experience a rapid onset of symptoms, have profound hypogonadism, have elevated prolactin levels, or have visual symptomatology.
Studies have shown that testosterone replacement therapy for hypogonadal men improves their sense of well-being, sexual function, mood, libido, bone density, muscle bulk, and muscle strength. It also may decrease visceral and peripheral body fat and can reduce insulin resistance and blood sugar.[4,5,8]
Treatment of hypogonadism can be provided through injectable testosterone esters, transdermal testosterone (gels or patches), or oral testosterone in the form of testosterone undecanoate. All of these delivery modes are acceptable in appropriate doses and allow patients the benefit of having a variety of options to choose from.
It may be necessary for practitioners to adjust the dose to suit a patient’s physiology, and switching to another delivery mode may be necessary if blood levels are not appropriate or if side effects such as polycythemia should occur.[4,5]
Some common delivery modes and recommended regimens for testosterone replacement therapy are as follows:
• Injection: 75 to 100 mg of testosterone enanthate or cypionate administered weekly, or 150 to 200 mg administered every other week.
• Patch: One or two 5 mg testosterone patches applied nightly on the skin of the back, thigh, or upper arm—away from pressure areas.
• Gel: 5 to 10 g of testosterone gel applied daily.
• Tablet: 80 mg of testosterone undecanoate taken orally twice a day with meals.
Table 2 lists some potential adverse effects of testosterone treatment. It is very uncommon to see a deterioration in mood with aggressiveness or anger as an outcome of testosterone treatment. Generally, this symptom complex is more often associated with hypogonadism, and mood in fact improves with restoration of the eugonadal state.
In patients with severe heart failure or liver disease, or occasionally among very elderly patients, testosterone treatment may result in mild fluid retention that requires dose adjustments or diuretic therapy.[4,5]
Men receiving testosterone therapy should be followed according to a standardized monitoring plan4,5 to ensure any potential side effects are detected early. Before initiating treatment, the practitioner should perform a digital rectal examination (DRE) and check the PSA level.
This should be done again at 3 months, and then in accordance with guidelines for prostate cancer screening, depending on the age and ethnicity of the patient. Testosterone levels should be assessed 2 to 3 months after therapy is initiated, as described in Table 3.
The goal is to raise serum testosterone levels to the mid-normal range. As well as assessing prostate health and testosterone levels, the practitioner should do the following:
• Evaluate the patient 3 months after treatment begins, and follow up with annual examinations to assess whether symptoms have improved and whether the patient is experiencing any adverse events.
• Obtain a baseline hematocrit value, check at 3 months, and then check annually. If hematocrit is greater than 52%, stop therapy until it decreases to a safe level and re-evaluate the patient for hypoxia and sleep apnea. If erythrocytosis develops with intramuscular (IM) therapy, three options exist: the dose can be reduced; the dose interval can be contracted with a lower dose per injection but a similar overall total dose per month; or a non-IM delivery mode can be used. Erythrocytosis is much less common with transdermal formulations, and extremely rare with oral testosterone undecanoate.
• Measure bone mineral density (BMD) of the lumbar spine or femoral neck (or both) after 1 to 2 years of testosterone therapy in hypogonadal men with osteoporosis or low-trauma fracture, consistent with regional standard of care.
• Request a urologic consultation in the following cases:
- Verified serum PSA concentration greater than 4.0 µg/L.
- Increase in serum PSA concentration greater than 1.4 µg/L within any 12-month period of testosterone treatment.
- PSA velocity greater than 0.4 µg/L/year, using the PSA level after 6 months of testosterone administration as a reference (only applicable if PSA data are available for at least 2 years).
- Prostatic abnormality is detected on DRE.
- AUA/IPSS (International Prostate Symptom Score) greater than 19.
• Evaluate formulation-specific adverse effects at each visit:
- Intramuscular injections of testosterone enanthate and cypionate: Ask about fluctuations in mood or libido.
- Testosterone patches: Look for skin reaction at the application site.
- Testosterone gels: Advise patients to cover the application sites with a shirt and to wash the skin with soap and water before having skin-to-skin contact because testosterone gel leaves a residue on the skin that can be transferred to a woman or child who comes in close contact. Serum testosterone levels are maintained when the site is washed 6 hours after applying the gel.
Cautions and considerations
Special considerations are necessary for testosterone treatment in patients with certain diseases. It is generally recommended that men with prostate cancer not be treated with androgens for fear of accelerating tumor growth.
However, opinions vary on treatment for men who are clearly hypogonadal and who have been successfully treated for prostate cancer in the past.[4,5] It is the author’s opinion that a year or two after successful surgical treatment for prostate cancer and in consultation with the patient’s urologist or oncologist, testosterone treatment can be provided for carefully selected patients under medical supervision and with informed consent.
There are currently no definitive studies suggesting that risk of prostate cancer is increased in hypogonadal men rendered eugonadal. Large, randomized, placebo-controlled studies in this area would be welcomed to definitely determine if any risk exists.
Testosterone and cardiovascular events
A recent study in the New England Journal of Medicine questioned the cardiovascular safety of testosterone therapy in aging men. The study was designed to assess whether testosterone replacement increased muscle strength for frail elderly men.
Although the results supported this hypothesis, they also suggested an increased rate of cardiovascular events in the subject group, and as a result the study was ended early.
It is important to note that the results of this study do not indicate a causal relationship between testosterone treatment and heart disease. The study was not designed to assess the risk of cardiovascular disease related to testosterone and, more importantly, there was a randomization failure with respect to the risk for adverse cardiovascular events.
More patients in the testosterone treatment arm of the study had hypertension or dyslipidemia, thereby predisposing them to cardiovascular disease and biasing the study outcome.
Meta-analyses exploring a possible connection between testosterone use and adverse coronary events have found no evidence of such a connection. Testosterone therapy in hypogonadal men has been shown to decrease angina, and testosterone deficiency is a marker for increased mortality in men with known coronary artery disease.
A multicentre study sponsored by the National Institutes of Health is presently under way in the United States to clarify the long-term cardiovascular effects of testosterone therapy in men. In the interim, a significantly hypogonadal man who has heart disease or is at risk for heart disease should not be refused testosterone therapy on the basis of cardiovascular risk.
It would be prudent, however, to monitor the man and to ensure his cholesterol levels are not adversely affected by the introduction of testosterone.
Testosterone and osteoporosis
Hypogonadism is a well-established cause of osteoporosis in men and women. Androgen deprivation in men increases the risk of osteoporosis and osteoporotic fractures.
Several trials have shown testosterone replacement therapy increases bone mineral density in hypogonadal men.[16-18] However, larger long-term studies are needed to assess whether fracture rates are lower in osteoporotic hypogonadal men treated with testosterone.
Testosterone and infertility
When healthy men are given replacement doses of testosterone, approximately two-thirds of them are rendered azoospermic. In short-term studies this outcome is completely reversible.
In hypogonadal men given testosterone, any residual sperm production present at the time of diagnosis will be further suppressed, and it is important that patients be informed about this side effect. For patients who wish to retain their fertility, androgen replacement can be deferred until their family is completed, or they may be offered alternative therapies.
For men with primary hypogonadism, the spermatogenic defect is not usually treatable. Men with secondary hypogonadism can usually be rendered fertile by either gonadotropin therapy or occasionally clomiphene citrate.
Androgen abuse by athletes
Misuse of androgens by competitive and recreational athletes is quite common and physicians should be alert to this. Both testosterone esters and synthetic testosterones are used.
Red flags for androgen abuse among men include small testes, low sperm count, high hematocrit and hemoglobin values, low serum SHBG, and undetectable LH and FSH concentrations. Alkylated testosterone compounds may also elevate liver function test results and dramatically lower HDL cholesterol, while recent use of injectable testosterone can increase creatine phosphokinase (CPK) levels.
Symptoms of hypogonadism can include mood changes, reduced libido, low energy, decreased muscle bulk and strength, hot flushes, decreased ability to concentrate, lack of morning erections, decreased volume of ejaculate, and infertility.
To confirm a diagnosis of hypogonadism physicians should look for:
• Symptoms of androgen deficiency.
• Unequivocal biochemical evidence of low testosterone levels.
• A positive response to testosterone replacement therapy.
The principal treatment for hypogonadism is testosterone replacement therapy, which can be delivered by injection, transdermally, or orally. Testosterone replacement therapy for hypogonadal men has been shown to improve sense of well-being, sexual function, mood, libido, bone density, and muscle bulk and strength. It also may decrease visceral and peripheral body fat and can reduce insulin resistance and blood sugar.
It is generally recommended that men with existing prostate cancer not be treated with androgens to avoid the possibility of accelerating tumor growth.
Hypogonadal men given testosterone will experience further suppression of sperm production. Patients who wish to retain their fertility should be informed about this side effect.
This article has been peer reviewed.
1. Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int J Clin Pract 2006;60:762-769.
2. Rosner W, Auchus RJ, Azziz R, et al. Utility, limitations and pitfalls in measuring testosterone: An Endocrine Society Position Statement. J Clin Endocrinol Metab 2007;92:405-413.
3. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004;89:3813-3817.
4. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-2559.
5. Morales A, Bella AJ, Chun S et al. A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians. Can Urol Assoc J 2010;4:269-275.
6. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983;56:1278-1281.
7. Brambilla DJ, O’Donnell AB, Matsumoto AM, et al. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf) 2007;67:853-862.
8. Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.
9. Wang C, Alexander G, Wagner G. Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 1996;81:3578-3583.
10. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2004;173:533-536.
11. Basaria S, Coviello AD, Travison TG. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-122.
12. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-1457.
13. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004;90:871-876.
14. Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821-1825.
15. Shahinian VB, Kou YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-164.
16. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-1972.
17. Amory JK, Watts NB, Sutton PR, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low testosterone. J Clin Endocrinol Metab 2004;89:503-510.
18. Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001;56:M266-M272.
Dr Bebb is an endocrinologist active in the Men’s Health Initiative of BC.
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org